N.N. Blokhin Memorial Cancer Research Center of Russian Federation
1995
MD
Tver State Medical Academy
1992
Research and Expertise
Research Interests
Dr. Leonid Metelitsa's research focuses on understanding the role of Va24-invariant natural killer T (NKT) cells in tumor immunity and translating this knowledge into NKT cell-based cancer immunotherapies. His group was the first to demonstrate that NKT cells localize to primary tumors in human patients and that presence of these cells at the tumor site is associated with favorable outcomes in the clinic (Metelitsa et al, JEM, 2004). Further studies revealed the underlying mechanistic basis of NKT cell tumor localization and function in the tumor microenvironment (Song et al, JCI, 2007; Song et al, JCI, 2009; Liu et al, JCI, 2012).
Based on the knowledge gained from studying NKT cell immunobiology, the Metelitsa group has developed original technologies and processes for NKT cell isolation, genetic modification with chimeric antigen receptors (CAR), and ex vivo expansion to clinical scale (Heczey et al, Blood, 2014; Tian et al, JCI, 2016). These efforts have resulted in initiation of a first-in-human CAR NKT cell clinical trial, GINAKIT2 (NCT03294954), that will test NKTs expressing an optimized second-generation GD2-specific CAR in children with neuroblastoma.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.